Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Getinge AB
  6. News
  7. Summary
    GETI B   SE0000202624

GETINGE AB

(GETI B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Getinge accelerates growth and productivity to reach new financial targets

11/22/2021 | 07:21am EST

"Getinge's new financial targets for 2022-2025, an annual organic net sales growth of 4-6% and adjusted EPS growth of above 10% on average throughout the period, is well in line with our strategy and ambitions", says Mattias Perjos, President & CEO at Getinge. "Our continued organic growth and improved margins will be fueled with bolt on M&A's for which we have significant capacity."

The base scenario for reaching the adjusted EPS growth target will be a gradual improvement of EBITA margin to 21% or more by the end of the period. In addition to this, further net sales growth and operating profit will be added from selective acquisitions, for which Getinge has significant capacity.

"Looking back at what we have accomplished since the Capital Markets Day in 2018, we have delivered growth of above 4% CAGR and an EBITA margin improvement of approximately 8 percentage points to 19.0%", continues Mattias Perjos. "We will continue to improve productivity, while we also gravitate our business growth towards product areas and markets with high growth and margins - both organically and through M&As."

Getinge has for the past years implemented its strategy which has lead to a significant increase in both customer and employee satisfaction. In addition, the company's product offering has been strengthened within growth areas and the company has set out an ambitions sustainabililty agenda for the coming years. In October 2021, the company announced the finalization of its remediation measures which enables Getinge to focus on more forward looking activities.

"Our solutions are needed more than ever to tackle global health care challenges", says Mattias Perjos. "We will continue to deliver value to our customers through our products, solutions and selective M&A's with a good strategic fit."

Getinge's Capital Markets Day will start at 3.00 pm (CET) and to participate at the event, please register via this link. More information will also be provided via Getinge's website. During the event, the company will present the next steps to strengthen the effects of the continuous improvement work and to take advantage of organic and acquisition related opportunities with increased intensity - given Getinge's unique technological competence, global presence and solid financial position.

This information is information that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 1.20 pm CET on November 22, 2021.
 

For more information:

Lars Mattsson, Head of Investor Relations
Telephone: +46 (0) 734 244 692
E-mail: lars.mattsson@getinge.com

About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.

https://news.cision.com/getinge/r/getinge-accelerates-growth-and-productivity-to-reach-new-financial-targets,c3457646

https://mb.cision.com/Main/942/3457646/1499663.pdf

https://news.cision.com/getinge/i/mattias-perjos,c2982651

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about GETINGE AB
01/19GETINGE : Cloud-based software solutions to support healthcare delivery
PU
01/17Getinge appoints Patricia Fitch as President North America Region
AQ
01/17Getinge appoints Elin Frostehav as President Acute Care Therapies and Eric Honroth as P..
AQ
01/17Getinge AB Appoints Elin Frostehav as President Acute Care Therapies and Eric Honroth a..
CI
01/17Getinge AB Announces Executive Changes, Effective April 1, 2022
CI
01/14GETINGE : Quadruplets safely delivered at the Regional Specialist Hospital in Wroclaw
PU
01/13GETINGE : program recognizes dedicated North American vessel harvesters
PU
01/10GETINGE ANNOUNCES ITS YEAR-END REPOR : 00 CET followed by a conference call at 10:00 CET
AQ
2021Getinge Buys US-based Talis Clinical For $66 Million
MT
2021Getinge acquires Talis Clinical LLC, a leading innovator of High Acuity cloud-based sof..
AQ
More news
Analyst Recommendations on GETINGE AB
More recommendations
Financials
Sales 2021 27 386 M 3 007 M 3 007 M
Net income 2021 2 958 M 325 M 325 M
Net Debt 2021 4 221 M 463 M 463 M
P/E ratio 2021 30,5x
Yield 2021 0,98%
Capitalization 90 345 M 9 932 M 9 919 M
EV / Sales 2021 3,45x
EV / Sales 2022 3,17x
Nbr of Employees 10 667
Free-Float 79,8%
Chart GETINGE AB
Duration : Period :
Getinge AB Technical Analysis Chart | GETI B | SE0000202624 | MarketScreener
Technical analysis trends GETINGE AB
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 331,70 SEK
Average target price 418,20 SEK
Spread / Average Target 26,1%
EPS Revisions
Managers and Directors
Mattias Sven Perjos President, Chief Executive Officer & Director
Lars Sandstr÷m Chief Financial Officer
Johan Malmquist Chairman
Anna Romberg Executive VP-Legal, Compliance & Governance
Johan Bygge Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GETINGE AB-16.05%9 932
MASIMO CORPORATION-23.61%12 328
PENUMBRA, INC.-23.90%8 168
NOVOCURE LIMITED-14.52%6 663
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.-12.96%5 134
SHOCKWAVE MEDICAL, INC.-18.81%5 112